Navigation Links
Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203
Date:1/28/2009

PRINCETON, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology. MDX-1203 is comprised of a potent cytotoxic prodrug chemically linked with a fully human anti-CD70 antibody. CD70 is expressed in renal cell carcinoma (RCC), leukemias, lymphomas, and other cancers. The Phase 1 study will evaluate MDX-1203 for the treatment of advanced/recurrent RCC and relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).

"Antibody-drug conjugates are another important and innovative therapeutic approach used to fight cancer by effectively and selectively killing tumor cells over-expressing specific tumor antigens, so we are extremely excited in achieving the IND filing for MDX-1203, the first candidate from our proprietary ADC technology platform," said Howard H. Pien, Chairman and CEO of Medarex. "We developed our ADC technology to have significant competitive advantages over existing technologies and the Phase 1 trial for MDX-1203 will be the first study to evaluate these potential benefits."

An open-label, multi-dose, dose-escalation Phase 1 clinical trial will be conducted in patients with RCC and NHL. This trial is designed to establish and evaluate the safety, tolerability and maximum tolerated dose, as well as preliminary distribution, metabolism and pharmacokinetics of MDX-1203.

About Medarex's Antibody-Drug Conjugate (ADC) Technology

Medarex has enhanced its core UltiMAb(R) antibody platform with a suite of technologies that optimize or augment the therapeutic activity of antibodies, and one important technology expansion is the company's pr
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... PALO ALTO, Calif., Oct. 26 Telik, Inc. (Nasdaq: ... HCl), the company,s lead therapeutic product candidate, has been ... of "The Top 10 Most Interesting Oncology Projects to ... to senior executives in the pharmaceutical, biotechnology, and medical ...
... Genomic Health , Inc. (Nasdaq: GHDX ) ... webcast on Monday, November 8 at 4:30 p.m. Eastern Time to ... will follow the release of the third quarter financial results after ... To access the live conference call on November 8 ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) is scheduled ... the Waldorf-Astoria Hotel in New York City on Tuesday, ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) (Logo: ... presentation will be accessible on the Company,s website at ...
Cached Biology Technology:TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 2TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 3Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 2Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... may have found a way to dramatically slow organ ... That's the promising implication of an animal study carried ... Birmingham (UAB) and the University of Florida (UF) published ... National Academy of Sciences. , The research team reported ...
... A drug first used to reduce the risk of stomach ... alternative to surgery after miscarriage, according to a study by ... Development of the National Institutes of Health and other research ... New England Journal of Medicine. , The drug, misoprostol, has ...
... protein design by a University of Houston professor will ... Nano Summit Research Conference July 28. , Kurt L. ... UH, will give a presentation at 11 a.m. on ... by the Nanotechnology Foundation of Texas, the 2005 Nano ...
Cached Biology News:Discoveries by UAB and Florida scientists may help transplanted organs survive longer 2Drug Offers Alternative to Surgical Treatment After Miscarriage 2Drug Offers Alternative to Surgical Treatment After Miscarriage 3Drug Offers Alternative to Surgical Treatment After Miscarriage 4Disease diagnosis, bioengineering covered at state nano summit 2
... Kit provides a fast and simple procedure for ... buffer exchange, and for removing different types of ... on spin-column chromatography using Norgens patented protein resin ... 2 , NaCl, KCl, CaCl 2 , LiCl, ...
... Surveyor software provides local instrument control ... HPLC Systems. The software operates on ... Windows Pocket PC 2002 O/S and ... directly to their Surveyor quaternary gradient ...
... Kit is a very sensitive immunohistochemical tool ... containing both anti-von Willebrand Factor and anti-CD31 ... variety of species. This AP kit provides ... of frozen and paraffin-embedded sections in human ...
... and MDS Sciex present the 4000 ... performance hybrid triple quadrupole/linear ion trap ... drug development or proteomics researcher. Innovative ... the leaders in mass spectrometry brings ...
Biology Products: